Across TCGA pan-cancer cohorts, BRD2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated BRD2 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher BRD2 Mutation is associated with better overall survival. In most high-consensus cancer types, elevated BRD2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

UCEC, PRAD, and STAD are the cancer types where BRD2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	All	0.970	0.650	.020	10	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
STAD	OS	Median	All	1.000	0.410	.046	3	view →
LUAD	OS	Median	II,III,IV	0.236	0.709	.034	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: BRD2 tumor-vs-normal RNA expression · all BRD2 data types